Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 6, 1997, Pages 1307-1312

  Mercier, Renee Claude ^a   Houlihan, Heather H ^a   Rybak, Michael J ^a,b  

^a DETROIT RECEIVING HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENTAMICIN; GLYCOPEPTIDE; METICILLIN; ORITAVANCIN; RIFAMPICIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ARTICLE; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; DRUG ACTIVITY; DRUG POTENTIATION; ENTEROCOCCUS FAECALIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

EID: 0030919648     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.6.1307     Document Type: Article

References (35)

1. Bailey, E. M., M. J. Rybak, and G. W. Kaatz. 1991. Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin. Antimicrob. Agents Chemother. 35:1089-1092.
2. Barrett, M. S., M. E. Erwin, and R. N. Jones. 1996. Antimicrobial activity of a new glycopeptide derivative, LY333328 tested against resistant gram-positive organisms, abstr. F203, p. 135. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
3. Bayer, A. S. 1993. Infective endocarditis. Clin. Infect. Dis. 17:313-322.
4. Centers for Disease Control and Prevention. 1993. Nosocomial enterococci resistant to vancomycin - United States, 1989-1993. Morbid. Mortal. Weekly Rep. 42:597-599.
5. Chambers, H. F., and S. Kennedy. 1990. Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis. Antimicrob. Agents Chemother. 34:510-514.
6. Craig, W. A., and S. C. Ebert. 1991. Killing and regrowth of bacteria in vitro: a review. Scand. J. Infect. Dis. 74:63-70.
7. Craig, W. A., and S. Gudmundsson. 1991. Postantibiotic efffect, p. 403-431. In V. Lorian (ed.), Antibiotics in laboratory medicine, 3rd ed. The Williams & Wilkins Co., Baltimore, Md.
8. Craig, W. A., and B. Suh. 1991. Protein binding and the antimicrobial effects: methods for determination of protein binding, p. 367-402. In V. Lorian (ed.), Antibiotics in laboratory medicine, 3rd ed. The Williams & Wilkins Co., Baltimore, Md.
9. Donabedian, S., M. B. Perri, L. A. Thal, and M. J. Zervos. 1996. Comparative in-vitro and bactericidal activity of LY333328 against multi-drug resistant enterococci, abstr. F204, p. 135. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
10. Eliopoulos, G. M., and R. C. Moellering. 1996. Antimicrobial combinations, p. 330-396. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. The Williams & Wilkins Co., Baltimore, Md.
11. Faville, R. J., D. E. Zaske, E. L. Kaplan, K. Crossley, L. D. Sabath, and P. G. Quite. 1978. Staphylococcus aureus endocarditis. Combined therapy with vancomycin and rifampin. JAMA 240:1963-1965.
12. Fekety, R. 1995. Vancomycin and teicoplanin, p. 346-354. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 4th ed. Churchill Livingston, New York, NY.
13. Gopal, V., A. L. Bisno, and F. J. Silverblatt. 1976. Failure of vancomycin treatment in Staphylococcus aureus endocarditis. In vivo and in vitro observations. JAMA 236:1604-1606.
14. Jacoby, G. A., and G. L. Archer. 1991. New mechanisms of bacterial resistance to antimicrobial agents. N. Engl. J. Med. 324:601-612.
15. Kang, S. L., and M. J. Rybak. 1995. Comparative in vitro activities of LY191145, a new glycopeptide, and vancomycin against Staphylococcus aureus and Staphylococcus-infected fibrin clots. Antimicrob. Agents Chemother. 39:2832-2834.
16. Lamp, K. C., and M. J. Rybak. 1993. Teicoplanin and daptomycin bactericidal activities in the presence of albumin or serum under controlled conditions of pH and ionized calcium. Antimicrob. Agents Chemother. 37:605-609.
17. Lamp, K. C., M. J. Rybak, E. M. Bailey, and G. W. Kaatz. 1992. In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob. Agents Chemother. 36:2709-2714.
18. Lencastre, H. D., B. M. L. D. Jonge, P. R. Matthews, and A. Tomasz. 1994. Molecular aspects of methicillin resistance in Staphylococcus aureus. J. Antimicrob. Chemother. 33:7-24.
19. Levine, D. P., B. S. Fromm, and B. R. Reddy. 1991. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann. Intern. Med. 115:674-680.
20. Lin, L., R. E. Stratford, L. L. Zornes, W. L. Confer, V. Vaseduvan, T. W. Jones, T. I. Nicas, U. A. Preston, C. J. Boylan, D. L. Zeckner, B. J. Boyll, P. A. Raab, N. J. Snyder, M. J. Zweifel, S. C. Wilkie, M. J. Rodriguez, R. C. Thompson, and R. D. G. Cooper. 1995. Non-clinical pharmacokinetics of LY333328, a semisynthetic glycopeptide antibiotic active against vancomycin-resistant enterococci, abstr. F254, p. 157. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
21. Massanari, R. M., and S. T. Donta. 1978. The efficacy of rifampin as adjunctive therapy in selected cases of staphylococcal endocarditis. Chest 73: 371-375.
22. McGrath, B. J., S. L. Kang, G. W. Kaatz, and M. J. Rybak. 1994. Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis. Antimicrob. Agents Chemother. 38:2034-2040.
23. Mobarakai, N., J. M. Quale, and D. Landman. 1994. Bactericidal activities of peptide antibiotics against multidrug-resistant Enterococcus faecium. Antimicrob. Agents Chemother. 38:385-387.
24. Moellering, R. C. 1992. Emergence of Enterococcus as a significant pathogen. Clin. Infect. Dis. 14:1173-1178.
25. Mulazimoglu, L., S. D. Drenning, and R. R. Muder. 1996. Vancomycin-gentamicin synergism revisited: effect of gentamicin susceptibility of methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 40: 1534-1535.
26. Nagarajan, R. 1993. Structure-activity relationships of vancomycin-type glycopeptide antibiotics. J. Antibiot. 46:1181-1195.
27. National Committee for Clinical Laboratory Standards. 1994. Approved standard. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. NCCLS document M7-A. National Committee for Clinical Laboratory Standards, Villanova, Pa.
28. Reymann, M. T., H. P. Holey, and C. G. Cobbs. 1978. Persistent bacteremia in staphylococcal endocarditis. Am. J. Med. 65:729-737.
29. Small, P. M., and H. F. Chambers. 1990. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob. Agents Chemother. 34:1227-1231.
30. Spera, R. V., and B. F. Farber. 1992. Multiple-resistant Enterococcus faecium. The nosocomial pathogen of the 1990s. JAMA 268:2563-2564.
31. Stanley, D., B. J. McGrath, K. C. Lamp, and M. J. Rybak. 1994. Effect of human scrum on killing activity of vancomycin and teicoplanin against Staphylococcus aureus. Pharmacotherapy 14:35-39.
32. Tailor, S. A. N., E. M. Bailey, and M. J. Rybak. 1993. Enterococcus, an emerging pathogen. Ann. Pharmacother. 27:1231-1242.
33. Watanakunakorn, C., and J. C. Tisone. 1982. Synergism between vancomycin and gentamicin or tobramycin for methicillin-susceptible and methicillin-resistant Staphylococcus aureus swains. Antimicrob. Agents Chemother. 22:903-905.
34. Zeckel, M. Personal communication.
35. Zelenitsty, S., J. Karlowsky, D. Hoban, A. Kabani, M. Zeckel, and G. Zhanel. 1996. Bactericidal activity of an investigational glycopeptide, LY333328, against vancomycin-sensitive and vancomycin-resistant Enterococcus faecium, abstr. F200, p. 135. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.